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Summary. Lactic acid bacteria (LAB) species are envisioned as promising vehicles for the mucosal delivery of therapeutic 
and prophylactic molecules, including the development of oral vaccines. In this study, we report on the expression of a synthetic 
nucleocapsid (NP) gene of infl uenza A virus in Lactobacillus casei. The NP gene was re-designed based on the tRNA pool and 
the codon usage preference of L. casei BL23. The codon-optimized NP gene was then cloned and expressed in L. casei RCEID02 
under the control of a constitutive promoter, that of the lactate dehydrogenase (ldh) gene. The synthetic NP gene was further 
expressed in L. casei EM116 under the control of an inducible promoter, that of the structural gene of nisin (nisA) from Lacto-
coccus lactis. Based on Western blot analysis, the specifi c protein band of NP, with a molecular mass of 56.0 kDa, was clearly 
detected in both expression systems. Thus, our study demonstrates the success of expressing a codon-optimized infl uenza A 
viral gene in L. casei. The suitability of the recombinant LAB strains for immunization purposes is currently under evaluation. 
[Int Microbiol 2013; 16(2):93-101]
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Introduction
There are numerous immunological benefi ts associated with 
vaccine administration by the mucosal route [20]. Moreover, 
because of economic, logistic, and safety reasons, the use of 
oral vaccines for large-scale immunization programs is an ex-
plicit objective of the World Health Organization (WHO) 
[30]. Among the different strategies for mucosal inmuniza-
tion, lactic acid bacteria (LAB) as live delivery vehicles of 
vaccine antigens have important advantages [31]. LAB, espe-
cially Lactobacillus and Lactococcus species, have been suc-
cessfully engineered to express antigenic proteins that could 
serve as live oral vaccines against various infectious diseases 
[3]. Several genes derived from bacterial [15], viral [14,19, 
22], parasitic [9], eukaryotic origin [32], and allergic proteins 
[24] have been cloned and expressed in these bacteria. Howe-
ver, the low level of production of the heterologous proteins is 
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one of the major drawbacks and might be a crucial limitation 
using LAB as an alternative vaccine system. Several strategies 
have been examined to improve the yield of the expressed 
proteins, including the use of strong promoters (of both cons-
titutive and inducible classes), high-copy-number plasmid 
vectors, and effi cient Shine–Dalgarno sequences [12]. Codon 
usage biases in LAB, including that in Lactobacillus casei, 
were shown to be an important factor affecting the translatio-
nal effi ciency of heterologous proteins [8]. The capability of 
heterologous protein expression is known to depend on the 
ability of bacterial tRNA to recognize the codon(s) of newly 
introduced genes [23]. Some codons not frequently present in 
L. casei genes (rare codons), such as AGG and AGA, both of 
which code for arginine (Arg), occur frequently in human ge-
nes [27]. This fi nding suggests the need to modify the coding 
sequence of the introduced gene according to the sequences 
frequently used by the bacterial host. For instance, the expres-
sion yield of a heterologous protein in Escherichia coli was 
increased up to 70 % compared to that of wild-type DNA se-
quence by using a codon-optimized gene [16].
Several complete genomes of LAB have now been se-
quenced, of which 59 are from the genus Lactobacillus [http://
www.ncbi.nlm.nih.gov/genome/browse/]. Genome sequence 
sizes range from the 1.26 megabase pairs (Mbp) of Lactoba-
cillus fl orum to the 3.43 Mbp of Lactobacillus plantarum. 
Comparative analysis and gene annotation of LAB genomes 
has allowed the prediction of tRNA in Lactobacillus species 
[17], which may help in codon optimization and therefore the 
success of heterologous protein expression in these bacteria.
The infl uenza virus is a major health problem throughout 
the world. Although presently available infl uenza vaccines 
stimulate the synthesis of neutralizing antibodies against the 
viral hemagglutinin (HA) and neuraminidase (NA) [2] pro-
teins, they only confer subtype-specifi c protection immunity. 
This is a major drawback, as the infl uenza virus undergoes 
continuous antigenic changes, which in turn requires conti-
nuous infl uenza surveillance and an annual vaccination pro-
gram to update protection against the circulating subtype [4]. 
Consequently, there is an important need to develop a univer-
sal infl uenza vaccine containing conserved viral component(s) 
eliciting broad-spectrum immunity against all viral subtypes. 
One of the most conserved infl uenza components among the 
different subtypes is the nucleocapsid (NP) protein. Studies 
on vaccines obtained by expressing the infl uenza NP gene 
have shown that cross-protective immune responses are pos-
sible [7]. Therefore, infl uenza vaccines based on the conser-
ved NP protein offer an alternative to confer protection against 
many, if not all, subtypes of infl uenza viruses.
In this study, we constructed two recombinant L. casei 
strains expressing a synthetic NP gene of the infl uenza A vi-
rus. The NP coding sequence was optimized based on the 
tRNA pool and the codon used by L. casei BL23. The codon-
optimized NP gene was cloned and expressed in L. casei un-
der the control of both constitutive and inducible promoters. 
The product of the synthetic gene in both cases was revealed 
by using commercial antibodies and Western blot, proving the 
success of our approach.
Materials and methods
Bacterial strains, culture media, and growth conditions. 
Table 1 lists the bacterial strains, cloning vectors, and primers used in this 
study. Escherichia coli strains were grown in Luria-Bertani (LB) broth 
(Difco, Franklin Lakes, NJ, USA) at 37 °C with shaking. Lactobacillus casei 
strains were cultured statically in de Man Rogosa and Sharpe (MRS) medium 
(Difco) at 37 °C. When needed, 15 g of biological grade agar (Difco)/l was 
added to the corresponding medium. Ampicillin (100 μg/ml) and erythromycin 
(2.5 μg/ml) (Sigma-Aldrich, St. Louis, MO, USA) were added as needed to 
the media for the selection of transformants in E. coli and L. casei, respecti-
vely. White/blue colony screening was performed for E. coli XL1-blue on LB 
plates supplemented with the appropriate antibiotic, 5-bromo-4-chloro-3-in-
dolyl β-D-galactopyranoside (20 mg/ml; X-Gal, Sigma-Aldrich), and iso-
propyl β-D-thiogalactopyranoside (0.5 M; IPTG, Sigma-Aldrich). 
Isolation of plasmid DNA. Plasmid DNA from L. casei was isolated 
and purifi ed as previously described [25]. Plasmid DNA from E. coli was 
isolated and purifi ed using the HiYield plasmid mini kit according to the ma-
nufacturer’s instructions (RBC Bioscience, Taiwan).
PCR amplifi cation. The Taq DNA polymerase-based amplifi cation was 
performed in 50 μl of PCR mixture, containing 50 mM KCl, 75 mM Tris-HCl 
(pH 9.0), 20 mM (NH4)2SO4, 1.5 mM MgCl2, 200 μM of each dNTP (dATP, 
dCTP, dGTP, and dTTP), 0.2 μM of each primer, and 1 U of Taq DNA 
polymerase. All reagents were molecular grade and were purchased from In-
vitrogen, Carlsbad, CA, USA. The 576-bp of nisA, the multiple cloning site 
(MCS), and the transcription terminator (TT) were PCR-amplifi ed under the 
following conditions: pre-denaturation (94 °C), denaturation (94 °C), annea-
ling (60 °C), extension (72 °C) and fi nal extension (72 °C) for 3 min, 30 s, 
30 s, 40 s, and 7 min respectively. The 1842-bp fusion gene consisting of the 
nucleocapsid gene and the transcription terminator (NP:TT) was amplifi ed 
under the following conditions: pre-denaturation (94 °C), denaturation 
(94 °C), annealing (60 °C), extension (68 °C) and fi nal extension (68 °C) for 
5 min, 30 s, 30 s, 1.30 min,c and 7 min, respectively.
DNA handling and transformation. The PCR products derived 
from PCR amplifi cation, or DNA fragments embedded in agarose gels, were 
purifi ed by using the HiYield Gel PCR DNA Fragments Extraction Kit 
(RBC). Electroporation of E. coli and L. casei were carried out as described 
by [6] and [5], respectively. All other DNA manipulations were essentially 
performed as described [28].
Verifi cation of the constructs. The correct nucleotide sequence and 
orientation of the cloned genes were confi rmed by DNA sequencing with a 
MegaBACE 1000 sequencer (Biodesign, Bangkok, Thailand) using specifi c 
primers (Table1). 
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Codon optimization of the NP gene for expression in Lacto-
bacillus casei. The native NP gene sequence of infl uenza A virus [A/
NewYork/31/2004(H3N2)] (GenBank accession no. CY000372) was retrie-
ved from the NCBI database [http://www.ncbi.nlm.nih.gov/nuccore/
CY000372]. The codon usage of the NP gene was compared with that of L. 
casei BL23 using a reference codon usage database [http://gib.genes.nig.
ac.jp/single/codon/main.php?spid=Lcas_BL23]. The codon-optimized NP 
gene was synthesized (Integrated DNA Technologies, San Diego, CA, USA) 
with 5′ and 3′ ends having NcoI (CCATGG) and XbaI (TCTAGA) sites, res-
pectively. The synthetic gene was supplied as a clone in pUC19, designated 
pIDTSMART-AMP-NP. The nucleotide sequence of the codon-optimized NP 
gene was deposited in NCBI database under accession number KC496021.
Determination of NP expression in Lactobacillus casei under 
the nisA and ldhL promoters. Both the recombinant L. casei EM116 
containing pLC13.9:NisA:NP:TT, designated as L. casei EM116:NP, and the 
Table 1. Bacterial strains, plasmids, and oligonucleotide primers used in this study
Materials Relevant characteristics Source or reference
Bacterial strains
Escherichia coli XL-1blue Electroporation host Stratagene
Lactobacillus casei RCEID02 Plasmid-free strain [26]
L. casei EM116 L. casei ATCC 393 derivative containing a chromosomal nisRK gene [18]
Plasmids Cloning vector
pGEM-T Easy vector Apr, vector harboring synthetic NP gene Promega
pIDTSMART-AMP-NP gene Apr and Emr, E. coli/L. casei cloning vector IDT
pRCEID-LC13.9 shuttle vector Apr, Plasmid containing LdhL promoter and GFPuv gene [26]
pGEM:LdhL:GFPuv Apr, Plasmid containing LdhL promoter and GFPuv gene [26]
pLC13.9:LdhL:NP:TT pRCEID-LC13.9 containg NP gene downstream of LdhL promoter This study
pLC13.9:NisA:NP:TT pRCEID-LC13.9 containg NP gene downstream of NisA promoter This study
pNZ8048 Inducible expression vector carrying NisA promoter, Cmr [13]
Oligonucleotides Sequence (5′–3′)
M13 (–40) forward gttttcccagtcacgac Promega
M13 (–48) reverse agcggataacaatttcacacagga Promega
p13.9F agggaataagggcgacac This study
p13.9R ccgcaggttcactagtagg This study
p13.9-F1 caccgaagcttcagctgaggttc (HindIII) [26]
pRep13.9-R gtaaaagcttaaacagctggagacaccc (HindIII) [26]
NPsynF1 acccacgtatgtgctcattg This study
synNPseq aataggtaccaatggcctcacaaggca (KpnI) This study
pnisAatII ccgagacgtcagtcttataactatactg (AatII) This study
pnisNdeI attacatatgaagctcgcgttatcggtc (NdeI) This study
Underlined nucleotides show the introduced restriction enzyme site, indicated in parentheses. 
Apr, Emr, and Cmr indicate the ampicillin, erythromycin, and chloramphenicol resistance gene, respectively.
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recombinant L. casei RCEID02 containing pLC13.9:LdhL:NP:TT, designa-
ted as L. casei RCEID02:NP, were examined for the production of NP pro-
tein. For the nisA-based inducible expression system, recombinant EM116:NP 
was cultured in MRS medium supplemented with 2.5 μg erythromycin/ml at 
37 °C. After the OD600 reached 0.3, nisin inducer was added to the culture at 
a fi nal concentration of 10 ng/ml. NP expression was monitored by sampling 
the bacterial cultures 1, 3, 5, 7, and 9 h after induction. The bacterial samples 
were washed twice with phosphate buffer saline (PBS, pH 7.0), and suspen-
ded in 300 μl of lysis buffer (0.5 M Na2HPO4, 5 M NaCl, 1 M imidazole 
[Qiagen, Hilden, Germany]), 100 mg lysozyme (Amresco, Salon, OH, USA)/
ml, 1× protease inhibitor cocktail (Amresco), and 1 M dithiothreitol [Amres-
co]). The bacterial cells were further broken by sonication with 10 pulses of 
30 s each with intermittent cooling. The whole-cell lysate was subjected to 
SDS-PAGE using 10 % polyacrylamide gels, followed by Western blot. The 
expressed NP was immunodetected by the sequential addition of mouse mo-
noclonal anti-H1N1 infl uenza A virus nucleocapsid protein (Abcam, Cam-
bridge, UK) at a dilution of 1/3000, goat anti-mouse IgG conjugated to hor-
seradish peroxidase (HRP) (Abcam) at a dilution of 1/15,000), and chemilu-
minescence substrate (SuperSignal West Pico Substrate; Thermo Fisher Sci-
entifi c, Rockford, IL, USA.). The crude cell lysate derived from MDCK cells 
(kindly provided by Dr. Parvapan Bhattarakosol, Faculty of Medicine, Chu-
lalongkorn University, Thailand) infected with infl uenza A virus H1N1 and 
the whole-cell lysates of L. casei strains EM 116 and RCEID02, containing 
the pRCEID-LC-13.9 empty vector, were used as positive and negative con-
trol, respectively.
For the ldhL-based constitutive expression system, recombinant RCEID02:NP 
was cultured in MRS media supplemented with 2.5 μg erythromycin/ml at 37 °C 
for 18 h. After incubation, the cells were harvested and the processes for sample 
preparation and detection of the expressed NP were followed as described above.
Results
Codon optimization of the infl uenza A virus 
NP gene for expression in Lactobacillus casei. 
We previously cloned and expressed a native NP gene of in-
fl uenza A virus in L. casei under the control of expression 
cassettes cloned into the pRCEID-LC13.9 cloning vector (Pa-
nya et al., unpublished). The expression cassette included pro-
moter and transcription termination sequences of the L. casei 
lactate dehydrogenase gene. Despite attempts to optimize he-
terologous protein expression in this species, Western blot 
analysis failed to show expression of the native NP gene. A 
literature survey suggested that heterologous gene expression 
could be enhanced by replacing native codons of the introdu-
ced gene with those naturally used by the host for its own 
highly expressed genes. Thus, in this study, the native codons 
of the NP gene were replaced with those preferentially used 
by L. casei BL23, as shown in Table 2.
The complete NP gene of infl uenza A virus is 1497 bp 
long, with 499 codons that are translated into 498 amino 
acids. Bioinformatics analysis of the viral NP codons showed 
that 44 codons are rare codons in L. casei: 22 AGA, 14 AGG, 
Table 2. Native- and codon-optimized nucleocapsid protein gene
Codon Codon
Amino acid      Native* Optimized Amino acid      Native* Optimized
Arg (R) AGA (22); AGG (14);  CGA (4); CGC (3); 
CGG (5); CGT (1) 
CGT Ser (S) AGC (8);  AGT (8); TCA (3); TCC (6); 
TCG (2); TCT (12)
TCA
Gly (G) GGA (18);  GGC (7); GGG (11); GGT (6) GGC Val (V) GTA (4); GTC (5); GTG (9); GTT (4) GTT
Leu (L) CTA (4); CTC (11); CTG (6); CTT (6); TTA 
(2); TTG (4)
TTG Ala (A) GCA (18); GCC (7); GCG (4); GCT (10) GCC
Pro (P) CCA (5); CCC (2); CCG (1); CCU (9) CCA Ile (I) ATA (8); ATC (13); ATT (6) ATC
Cys (C) TGC (5); TGT (1) TGC Gln (Q) CAA (15); CAG (6) CAA
Thr (T) ACA (8); ACC (7); ACG (3);  ACT (10); 
ACT (10)
ACC Asn (N) AAC (7); AAT (20) AAC
Lys (K) AAA (14); AAG (7) AAA Asp (D) GAC (11); GAT (11) GAT
Phe (F) TTC (11); TTT (7) TTC His (H) CAC (3); CAT (3) CAT
Tyr (Y) TAC (9); TAT (6) TAT Glu (E) GAA (23); GAG (13) GAA
Met (M) ATG (25) ATG Trp (W) TGG (6) TGG
*In parentheses, the number of each codon found in the native NP sequence. 
Rare codons found in the native NP gene are shown in bold.
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and 8 ATA codons (Table 2). For codon optimization of the 
NP gene, the AGA and AGG, which code for arginine (R), 
were replaced with CGT; ATA, which codes for isoleucine (I), 
was replaced with ATC. In addition, some of the remaining 
native NP codons were replaced with the corresponding co-
dons predicted to be highly used by L. casei BL23. For exam-
ple, all codons that code for arginine, i.e. CGA, CGC, CGG, 
including two rare codons (AGA and AGG), were replaced 
with the optimized codon CGT. With this approach, a total of 
321 codons were changed, as shown in Table 2. Some restric-
tion endonuclease sites in the native NP gene, including four 
PstI, three HindIII, two BamHI and a single EcoRV site, were 
removed by this replacement. To facilitate cloning of the opti-
mized NP gene into the expression vector, the gene was synt-
hesized with the addition of the NcoI (CCATGG), overlap-
ping the initial ATG codon, and XbaI (TCTAGA) recognition 
sequences at the 5′- and 3′-end, respectively. This optimized 
NP gene, with a total length of 1505 base pairs, was cloned 
into pUC19 digested with both NcoI and XbaI, and the resul-
ting construct was designated pIDTSMART-AMP-NP. The 
synthesis was externally constructed (Integrated DNA Tech-
nologies, San Diego, CA, USA). 
Fig. 1. Schematic diagram of the cons-
truction of the recombinant plasmid 
pLC13.9:NisA:NP:TT. Positions amp, 
ery, ori, and repA1 indicate ampicillin 
resistance gene, erythromycin resistance 
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Construction of recombinant expression plas-
mids containing the codon-optimized NP gene. 
In this study, two NP-expression systems were constructed, one 
based on the nisin gene (nisA)-inducible promoter and the other 
on the constitutive promoter of the lactate dehydrogenase gene 
(ldhL). For the NisA-based expression system (Fig. 1), the PCR 
product containing the nisA gene promoter, the multiple clo-
ning site (MCS), and the transcription terminator signals (TT) 
from pNZ8048 were amplifi ed with the primer pair pnisAatII 
and pnisNdeI (Table 1) and the obtained amplicons were cloned 
into the pGEM-T-Easy vector to generate pNisA. The codon-
optimized NP gene was released from pIDTSMART-AMP-NP 
by NcoI and XbaI digestion and the fragment was isolated and 
purifi ed from an agarose gel. The DNA segment was cloned 
into pNisA digested with the same restriction enzymes; the re-
sulting construct was named pNisA:NP:TT. A DNA fragment 
from this construct digested with AatII and NdeI was isolated 
from a gel and subcloned into the E. coli/L. casei shuttle vector 
pRCEID-LC13.9 (Table 1) digested with the same enzymes. 







Fig. 2. Schematic diagram of 
the construction of the recom-
binant plasmid pLC13.9:LdhL: 
NP:TT. Positions amp, ery, 
ori, and repA1 indicate ampi-
cillin resistance gene, erythro-
mycin resistance gene, origin 
of replication and replicon A1, 
respectively.
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For the construction of the ldhL-based expression system 
(Fig. 2), the NP:TT fragment was amplifi ed from pNisA:NP:TT 
using the primer pair NPsynF1 and pnisNdeI (Table1) and 
then inserted into KpnI/NdeI-digested pGEM:LdhL:GFPuv 
(Table 1) to generate pLdhL:NP:TT. The LdhL:NP:TT frag-
ment was isolated and purifi ed from pLdhL:NP:TT after di-
gestion with AatII and NdeI and cloned into the pRCEID-
LC13.9 vector. The fi nal construct, designated pLC13.9: 
LdhL:NP:TT, and pLC13.9:NisA:NP:TT were verifi ed by 
DNA sequencing and analysis. Purifi ed plasmids from these 
verifi ed constructs were transformed into L. casei EM116 and 
RCEID02, respectively, to generate the recombinant lactoba-
cilli strains L. casei EM116:NP and L. casei RCEID:NP, 
carrying the former and the latter construct, respectively. As 
the negative control, the empty plasmid vector, pRCEID-
LC13.9, was also transformed into both EM116 and RCEID02. 
Expression of NP protein in Lactobacillus casei 
under different expression systems. Western blot-
ting using a specifi c antibody against NP showed that both 
L. casei EM116:NP and RCEID:NP expressed NP (Fig. 3A,B). 
The expression of NP in the nisin inducible system was con-
fi rmed by the detection of a protein with the expected size of 
56 kDa 3 and 5 h after nisin induction (10 ng nisin/ml). Ex-
pression declined slightly at 7 h and was completely absent at 
9 h (Fig. 3A). Figure 3B shows NP expression by L. casei 
strain RCEID02:NP. Taken together, our results indicated that 
codon-optimization is a successful strategy for the expression 
of the NP gene in L. casei, both under the nisA and the ldhL 
promoters.  
Using the same constructs, we further analyzed the ex-
pression of codon-optimized NP gene in E. coli XL1. As 
shown in Fig. 3B, recombinant E. coli cells containing 
pLC13.9:LdhL:NP:TT (XL1:NP) synthesized the 56-kDa NP 
protein under the ldhL promoter, whereas expression was not 
observed in E. coli under the control of the nisA-inducible 
expression system (data not shown).
Discussion
Currently, heterologous gene expression is being actively in-
vestigated in LAB as live vehicles for the mucosal delivery 
of therapeutic and prophylactic proteins. However, the low-
level expression of heterologous genes in these bacteria is an 
important drawback that limits their application for such pur-
poses. 
Codon usage bias in LAB has been shown to reduce trans-
lational effi ciency and, thus, the total amount of protein synt-
hesized [8]. The expression level of genes containing codons 
matching those of the bacterial hosts is higher than that of 
genes containing native codons [16]. In L. casei, three codons 
(AGG and AGA, coding for arginine, and ATA, coding for 







Fig. 3.  (A) Immunodetection of the expressed NP in crude cell lysates of Lactobacillus casei 
EM116, as revealed with mouse anti-NP monoclonal antibodies at different times of nisin 
induction. Lane 1, crude cell lysate from infl uenza A virus (H1N1)-infected cells. Lanes 2, 3, 
4, 5, and 6, nisin-induced EM116:NP cell lysates at 1, 3, 5, 7, and 9 h after nisin induction, 
respectively. Lane 7, L. casei EM116 harboring the pRCEID-LC13.9 shuttle cloning vector. The 
arrow points to the NP band, with a molecular mass of 56 kDa. (B) Immunodetection of the 
expressed NP in crude cell lysates of RCEID02:NP and XL1:NP using mouse anti-NP monoclonal 
antibodies. Lane 1, Escherichia coli cells containing the pRCEID-LC13.9 shuttle cloning vector. 
Lane 2, crude cell lysate from infl uenza A virus (H1N1)-infected cells. Lane 3, XL1:NP. Lane 4, 
RCEID02:NP. Lane 5, L. casei RCEID02 containing pRCEID-LC13.9. The arrow points to the 
NP band, with a molecular mass of 56 kDa.
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[27]. Bioinformatic analysis showed that the infl uenza A virus 
NP gene contains 22 AGA, 14 AGG, and 8 ATA codons. All 
these rare codons were replaced by the codons used by L. 
casei BL23. To obtain more effective translation, additional 
codon replacement was achieved with codons that are fre-
quently used by L. casei BL23 (Table 2). Codon optimizati-
on thus resulted in the removal of four PstI, three HindIII, 
two BamHI, and a single EcoRV site from the optimized NP 
gene. The loss of these restriction sites allowed for greater 
fl exibility in the choice of restriction sites used for cloning 
the NP gene in the cloning vector. In a previous study, we 
were unable to obtained the expression of the native NP co-
ding sequence as protein in L. casei, although expression 
was not quantitatively determined (data not shown). As re-
ported previously by other authors, the translation of hetero-
logous genes containing a high percentage of rare codons is 
generally stalled or prematurely terminated, which results in 
a low level of expression [1]. 
Since the stability (both segregational and structural) of a 
plasmid in a bacterial host is a necessary requirement in the 
generation of live vaccines. in this study we used the pR-
CEID-LC13.9 E. coli/L. casei shuttle vector, which is highly 
stable in lactobacilli, as the backbone plasmid [26]. Codon-
optimized NP was cloned under the control of the lactate 
dehydrogenase (ldhL) gene promoter and under the nisA pro-
moter in L. casei RCEID02 and EM116, respectively. Further 
stability was assured by the presence of a rho-independent 
terminator at the 3′N-terminal of the NP gene. Note that the 
growth rate of transformants containing recombinant plas-
mids was similar to that of wild-type lactobacilli. Furthermore, 
the constructs were highly stable, without appreciable gene 
rearrangements (structural stability) or plasmid loss during 
bacterial growth (segregational stability), even after 80 gene-
rations (data not shown). 
The ldhL promoter is a constitutive gene expression 
system that does not require an inducer, and it has been suc-
cessfully used for both homologous and heterologous gene 
expression in many lactobacilli species [10,11,29]. The nisA-
based expression system, by contrast, is a regulated gene ex-
pression system that is often used to prevent the toxicity of the 
expressed proteins [21]. Thus, the expression of a given gene 
can be modulated by the use of a convenient expression 
system. 
Western blot assays showed that the specifi c protein band 
of NP, with a molecular mass of 56.0 kDa, was clearly detec-
ted when expressed in either system. However, higher levels 
of expression were obtained with the nisA expression system 
in L. casei EM116. Our study therefore clearly demonstrates 
the cloning and expression of an infl uenza A gene in L. casei. 
Similar results were previously reported for the expression in 
L. casei of the VP60 protein of Norwalk virus [19].
In conclusion, in this study we describe the use of codon-
optimization in the NP gene of infl uenza A virus, which allo-
wed its successful cloning and expression in L. casei strains, 
using the E. coli/L. casei shuttle vector pRCEID-LC13.9. Ex-
pression of the NP gene in L. casei would facilitate the use of 
this bacterium in the immunization against infl uenza A virus.
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